L01EB Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors
ATC class of level 4 – chemical subgroup
This page lists the patient medication information or the product monograph for 16 drugs in this drug class and its subclasses.
- 16 prescription (Rx)
Place in the ATC system
- L Antineoplastic and immunomodulating agents 1,069 drugs
- L01 Antineoplastic agents 616 drugs
- L01E Protein kinase inhibitors, antineoplastic and immunomodulating agents 118 drugs
-
L01EB Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors 16 drugs
- L01EB01 Gefitinib 4 drugs
- L01EB02 Erlotinib 5 drugs
- L01EB03 Afatinib 4 drugs
- L01EB04 Osimertinib 1 drug
- L01EB07 Dacomitinib 1 drug
- L01EB09 Lazertinib 1 drug
-
L01EB Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors 16 drugs
- L01E Protein kinase inhibitors, antineoplastic and immunomodulating agents 118 drugs
- L01 Antineoplastic agents 616 drugs
Active ingredients of the class
- Afatinib (afatinib dimaleate) 4 drugs
- Dacomitinib (dacomitinib monohydrate) 1 drug
- Erlotinib (erlotinib hydrochloride) 5 drugs
- Gefitinib 4 drugs
- Lazertinib (lazertinib mesylate) 1 drug
- Osimertinib (osimertinib mesylate) 1 drug
Drugs in the class and its subclasses
| Drug | Rx or OTC |
|---|---|
| Apo-Erlotinib PM (L01EB02 Erlotinib) | prescription (Rx) |
| Apo-Gefitinib PM (L01EB01 Gefitinib) | prescription (Rx) |
| Auro-Gefitinib (L01EB01 Gefitinib) | prescription (Rx) |
| Eugia-Gefitinib (L01EB01 Gefitinib) | prescription (Rx) |
| Giotrif PM (L01EB03 Afatinib) | prescription (Rx) |
| Lazcluze PM (L01EB09 Lazertinib) | prescription (Rx) |
| Mar-Afatinib PM (L01EB03 Afatinib) | prescription (Rx) |
| Nat-Erlotinib PM (L01EB02 Erlotinib) | prescription (Rx) |
| Nat-Gefitinib (L01EB01 Gefitinib) | prescription (Rx) |
| PMS-Erlotinib PM (L01EB02 Erlotinib) | prescription (Rx) |
| Sandoz Afatinib (L01EB03 Afatinib) | prescription (Rx) |
| Tagrisso (L01EB04 Osimertinib) | prescription (Rx) |
| Tarceva (L01EB02 Erlotinib) | prescription (Rx) |
| Teva-Afatinib PM (L01EB03 Afatinib) | prescription (Rx) |
| Teva-Erlotinib PM (L01EB02 Erlotinib) | prescription (Rx) |
| Vizimpro (L01EB07 Dacomitinib) | prescription (Rx) |
Other classes of the same level
- L01EA BCR-ABL tyrosine kinase inhibitors 30 drugs
- L01EC B-Raf serine-threonine kinase (BRAF) inhibitors 3 drugs
- L01ED Anaplastic lymphoma kinase (ALK) inhibitors 4 drugs
- L01EE Mitogen-activated protein kinase (MEK) inhibitors 5 drugs
- L01EF Cyclin-dependent kinase (CDK) inhibitors 7 drugs
- L01EG Mammalian target of rapamycin (mTOR) kinase inhibitors 1 drug
- L01EH Human epidermal growth factor receptor 2 (HER2) tyrosine kinase inhibitors 5 drugs
- L01EJ Janus-associated kinase (JAK) inhibitors 3 drugs
- L01EK Vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors 3 drugs
- L01EL Bruton's tyrosine kinase (BTK) inhibitors 4 drugs
- L01EM Phosphatidylinositol-3-kinase (Pi3K) inhibitors 3 drugs
- L01EX Other protein kinase inhibitors 30 drugs
Other names of the drug class
- English (United Kingdom): L01EB Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors
- German: L01EB Epidermaler Wachstumsfaktor-Rezeptor (EGFR)-Tyrosinkinase-Inhibitoren
- German (Austria): L01EB Epidermaler Wachstumsfaktor-Rezeptor (EGFR)-Tyrosinkinase-Inhibitoren
- Italian: L01EB Inibitore del recettore per il fattore di crescita epidermico (EGFR)
- Turkish: L01EB Epidermal büyüme faktörü reseptörü (EGFR) tirozin kinaz inhibitörleri
- Czech: L01EB Tyrosinkinázové inhibitory receptoru pro epidermální růstový faktor (EGFR)
- Slovak: L01EB Inhibítory receptora epidermálneho rastového faktora (EGFR) tyrozínkinázy
- German (Switzerland): L01EB Epidermaler Wachstumsfaktor-Rezeptor (EGFR)-Tyrosinkinase-Inhibitoren
- Italian (Switzerland): L01EB Inibitore del recettore per il fattore di crescita epidermico (EGFR)
- Dutch: L01EB Epidermale groeifactorreceptor(EGFR)-tyrosinekinaseremmers
Sources
- Patient medication information and product monographs: Health Canada, Drug Product Database
- Active ingredients, ATC codes and Rx or OTC status: Health Canada, Drug Product Database
- World Health Organization (WHO): ATC/DDD system, class L01EB
Ask your doctor or pharmacist for advice.
